Page last updated: 2024-09-05

enzastaurin and bortezomib

enzastaurin has been researched along with bortezomib in 8 studies

Compound Research Comparison

Studies
(enzastaurin)
Trials
(enzastaurin)
Recent Studies (post-2010)
(enzastaurin)
Studies
(bortezomib)
Trials
(bortezomib)
Recent Studies (post-2010) (bortezomib)
18852996,8688604,753

Protein Interaction Comparison

ProteinTaxonomyenzastaurin (IC50)bortezomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)0.5335
Proteasome subunit alpha type-7Homo sapiens (human)0.3213
Histone deacetylase 3Homo sapiens (human)1.18
26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)0.5335
Cathepsin GHomo sapiens (human)1.81
Lysosomal protective proteinHomo sapiens (human)9.2
26S proteasome regulatory subunit 6AHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)0.085
Proteasome subunit beta type-1Homo sapiens (human)0.2149
ChymaseHomo sapiens (human)1.19
Proteasome subunit alpha type-1Homo sapiens (human)0.3213
Proteasome subunit alpha type-2Homo sapiens (human)0.3213
Proteasome subunit alpha type-3Homo sapiens (human)0.3213
Proteasome subunit alpha type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-8Homo sapiens (human)0.1681
Proteasome subunit beta type-8Mus musculus (house mouse)0.0168
Proteasome subunit beta type-9Homo sapiens (human)0.2059
Proteasome subunit alpha type-5Homo sapiens (human)0.3213
Proteasome subunit beta type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-6Homo sapiens (human)0.2842
Proteasome subunit beta type-5Homo sapiens (human)0.1407
26S proteasome regulatory subunit 7Homo sapiens (human)0.5335
Lon protease homolog, mitochondrialHomo sapiens (human)0.183
Proteasome subunit beta type-10Homo sapiens (human)0.5359
26S proteasome regulatory subunit 6BHomo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)0.5335
Proteasome subunit beta type-3Homo sapiens (human)0.3213
Proteasome subunit beta type-2Homo sapiens (human)0.9297
26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome complex subunit SEM1Homo sapiens (human)0.5335
Proteasome subunit alpha type-6Homo sapiens (human)0.3213
26S proteasome regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome regulatory subunit 8Homo sapiens (human)0.5335
26S proteasome regulatory subunit 10BHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)0.085
Transcription factor p65Homo sapiens (human)0.085
26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)0.5335
Histone deacetylase 1Homo sapiens (human)0.62
26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)0.5335
Proteasomal ubiquitin receptor ADRM1Homo sapiens (human)0.5335
ATP-dependent Clp protease proteolytic subunitStaphylococcus aureus subsp. aureus NCTC 83255.3
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)0.0407
Proteasome subunit alpha-type 8Homo sapiens (human)0.3213
Histone deacetylase 2Homo sapiens (human)0.8
Proteasome subunit beta type-7Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)0.5335
Histone deacetylase 8Homo sapiens (human)0.072
26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)0.5335

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's7 (87.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Barrientos, J; Elstrom, R; Leonard, JP; Martin, P1
Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y1
Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE1
Ghobrial, IM; Roccaro, AM; Sacco, A1
Ogura, M1
Chang, H; Chen, GA; Chen, J; Chen, Y; Evans, K; Qiu, L; Reece, D; Saha, MN; Yang, Y1
Bari, A; Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S1

Reviews

2 review(s) available for enzastaurin and bortezomib

ArticleYear
Targeted treatment and new agents in diffuse large B-cell lymphoma.
    Seminars in hematology, 2008, Volume: 45, Issue:3 Suppl 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Delivery Systems; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Inhibitor of Apoptosis Proteins; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Protein Kinases; Pyrazines; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome; Vorinostat

2008
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Endothelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Protease Inhibitors; Proteasome Inhibitors; Protein Kinase C; Pyrazines; TOR Serine-Threonine Kinases; Tumor Microenvironment; Waldenstrom Macroglobulinemia

2011

Trials

2 trial(s) available for enzastaurin and bortezomib

ArticleYear
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
    American journal of hematology, 2011, Volume: 86, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors

2011
[Current development of new drugs in malignant lymphoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat

2012

Other Studies

4 other study(ies) available for enzastaurin and bortezomib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
    Talanta, 2010, Feb-15, Volume: 80, Issue:4

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence

2010
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Leukemia, 2015, Volume: 29, Issue:3

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Transplantation; Phosphorylation; Primary Cell Culture; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Survival Analysis

2015
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
    Hematological oncology, 2015, Volume: 33, Issue:4

    Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Indoles; Lenalidomide; Lymphoma, Mantle-Cell; Male; Signal Transduction; Thalidomide

2015